Contrarius Group Holdings Ltd Has $6.42 Million Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Contrarius Group Holdings Ltd lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 87.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 714,480 shares of the company’s stock after selling 5,175,456 shares during the quarter. Contrarius Group Holdings Ltd owned 0.62% of Intellia Therapeutics worth $6,423,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Intellia Therapeutics by 17.8% in the fourth quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after acquiring an additional 1,965,181 shares during the last quarter. Baker BROS. Advisors LP increased its position in Intellia Therapeutics by 2.7% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock worth $47,435,000 after purchasing an additional 71,000 shares in the last quarter. Geode Capital Management LLC increased its position in Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after purchasing an additional 107,333 shares in the last quarter. Two Sigma Investments LP increased its position in Intellia Therapeutics by 7.6% during the 3rd quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock worth $42,305,000 after purchasing an additional 173,033 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its position in Intellia Therapeutics by 3.7% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,610,205 shares of the company’s stock worth $27,808,000 after purchasing an additional 56,971 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on NTLA shares. The Goldman Sachs Group increased their price target on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research note on Tuesday, April 28th. Citizens Jmp increased their price target on Intellia Therapeutics from $28.00 to $30.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group cut their price target on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, reissued a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and an average target price of $20.25.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $13.54 on Monday. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -3.82 and a beta of 1.92. Intellia Therapeutics, Inc. has a twelve month low of $7.75 and a twelve month high of $28.25. The stock has a fifty day simple moving average of $13.61 and a 200 day simple moving average of $12.17.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. During the same period in the prior year, the business posted ($1.10) earnings per share. Research analysts expect that Intellia Therapeutics, Inc. will post -3.23 earnings per share for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.